Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio 
Welcome,         Profile    Billing    Logout  
 26 Diseases   30 Trials   30 Trials   518 News 


«12345678910111213»
  • ||||||||||  Anktiva (inbakicept) / ImmunityBio
    Trial completion, Trial completion date:  Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT (clinicaltrials.gov) -  Jan 6, 2023   
    P2,  N=20, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Jan 2023 --> Aug 2022
  • ||||||||||  Opdivo (nivolumab) / BMS, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
    Trial completion date, Trial primary completion date:  ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Dec 7, 2022   
    P1/2,  N=58, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=80 --> 23 Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Oct 2022 --> Mar 2023
  • ||||||||||  CIML NK - Dana / Farber Cancer Institute
    Trial completion date, Trial primary completion date, Combination therapy, Metastases, Immune cell:  CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) -  Dec 6, 2022   
    P1,  N=12, Recruiting, 
    Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Oct 2022 --> Mar 2023 Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  teropavimab (GS-5423) / Rockefeller University, Gilead, zinlirvimab (GS-2872) / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead
    Enrollment open:  3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803) (clinicaltrials.gov) -  Nov 3, 2022   
    P1,  N=36, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Anktiva (inbakicept) / ImmunityBio
    Journal:  IL-15 Superagonist N-803 Enhances IFN-γ Production of MAIT Cells in SIV Macaques. (Pubmed Central) -  Oct 25, 2022   
    Finally, N-803 improved the ability of MAIT cells collected from PBMC and airways to produce IFN-γ in response to bacterial stimulation. Overall, N-803 shows the potential to transiently alter the phenotypes and functions of MAIT cells, which could be combined with other strategies to combat bacterial infections.
  • ||||||||||  Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer (clinicaltrials.gov) -  Oct 6, 2022   
    P2,  N=7, Completed, 
    Overall, N-803 shows the potential to transiently alter the phenotypes and functions of MAIT cells, which could be combined with other strategies to combat bacterial infections. Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Feb 2022 | Trial primary completion date: Sep 2021 --> Feb 2022
  • ||||||||||  teropavimab (GS-5423) / Rockefeller University, Gilead, zinlirvimab (GS-2872) / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead
    Trial completion date, Trial initiation date, Trial primary completion date:  3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803) (clinicaltrials.gov) -  Sep 14, 2022   
    P1,  N=36, Not yet recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Feb 2022 | Trial primary completion date: Sep 2021 --> Feb 2022 Trial completion date: Sep 2025 --> Dec 2025 | Initiation date: Aug 2022 --> Nov 2022 | Trial primary completion date: Sep 2024 --> Dec 2024
  • ||||||||||  Anktiva (inbakicept) / ImmunityBio
    Preclinical, Review, Journal:  Clinical and Preclinical Therapies for Bladder Cancer Following BCG Failure. (Pubmed Central) -  Sep 7, 2022   
    In terms of toxicity/complication rates, both commercially available and unavailable treatments showcase low toxicity profiles for bladder cancer following BCG failure. The comprehensive analysis provided by this systematic review can serve as a reference for treatment decisions and clinical trial design in the BCG-unresponsive domain.
  • ||||||||||  Opdivo (nivolumab) / BMS, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
    Trial completion date, Trial primary completion date:  ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Aug 10, 2022   
    P1/2,  N=58, Active, not recruiting, 
    As such, pharmacological enhancement of IL-15-mediated STAT activation can open new therapeutic avenues toward an HIV cure. Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Jun 2022 --> Oct 2022
  • ||||||||||  CIML NK cells / Washington University School of Medicine in St. Louis
    Trial completion date, Trial primary completion date:  Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) -  Aug 9, 2022   
    P2,  N=60, Recruiting, 
    Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Jun 2022 --> Oct 2022 Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
  • ||||||||||  Anktiva (inbakicept) / ImmunityBio
    Enrollment closed, Enrollment change, Trial primary completion date:  Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease (clinicaltrials.gov) -  Jul 8, 2022   
    P1,  N=23, Active, not recruiting, 
    Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025 Recruiting --> Active, not recruiting | N=10 --> 23 | Trial primary completion date: Feb 2023 --> Jul 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Anktiva (inbakicept) / ImmunityBio
    Journal, Cancer stem cells:  Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells. (Pubmed Central) -  Jun 30, 2022   
    Flow cytometric analysis of a chordoma CSC population showed that CSCs expressed significantly more NK activating ligand B7-H6 and PD-L1 than non-CSCs, thus explaining a potential mechanism of selective targeting. These data suggest that chordoma may be effectively targeted by combinatorial NK cell-mediated immunotherapeutic approaches and that the efficacy of these approaches in chordoma and other CSC-driven tumor types should be investigated further in clinical studies.